| Gene symbol | TTR | Synonyms | ATTR, CTS, CTS1, HEL111, HsT2651, PALB, TBPA, TTN | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | transthyretin | ||||
| GTO ID | GTC1463 |
| Trial ID | NCT01981837 |
| Disease | Amyloidosis |
| Altered gene | TTR |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | ALN-TTRSC|revusiran |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis |
| Year | 2013 |
| Country | United States|United Kingdom |
| Company sponsor | Alnylam Pharmaceuticals |
| Other ID(s) | ALN-TTRSC-002 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||